健脾养血方联合化疗治疗胃癌的临床效果

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (618 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy and safety evaluation of Jianpi Yangxue Decoction combined with Capecitabine and Oxaliplatin (CAPOX) chemotherapy for patients with gastric cancer. Methods A total of 120 gastric cancer patients admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from January 2018 to December 2020 were selected as the research subjects, and they were divided by lottery into observation group (Jianpi Yangxue Decoction + CAPOX chemotherapy regimen) and control group (CAPOX chemotherapy regimen), with 60 patients in each group. After two sessions, traditional Chinses medicine syndrome score, the Eastern Cooperative Oncology Group (ECOG) score, tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen 19-9 [CA19-9]) levels, and the occurrence of adverse reaction of chemotherapy (Ⅱ-Ⅳ degrees of bone marrow supression [white blood cells, platelets, hemoglobin], liver and kidney function, gastrointestinal reaction, and peripheral nerve toxicity) were compared in two groups. Results There were six cases of detachment in the observation group and five cases in the control group, and 109 cases were included in the study. After treatment, traditional Chinses medicine syndrome score, CEA, and CA19-9 levels in both groups were lower than those before the treatment, and the observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). ECOG score of observation group before and after treatment had no statistical significance (P ＞ 0.05). After treatment, the ECOG score of the control group was higher than that before the treatment, and observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). The incidences of hemoglobin Ⅱ-Ⅳ degrees of bone marrow supression, gastrointestinal reaction, and peripheral neurotoxicity in the observation group were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). Conclusion After the addition of Jianpi Yangxue Decoction to gastric cancer patients receiving chemotherapy, it can improve the traditional Chinses medicine symptoms, quality of life, and the expression of tumor markers, reduce the adverse reactions caused by chemotherapy, and play a synergistic and toxic role.

Key words： Gastric cancer Chemotherapy Toxic side effect Chinese medicine therapy Jianpi Yangxue Decoction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Chengyin1 XU Yifang1 ZHAO Jingling2 GONG Hongwei1 JU Mengying3 YANG Jie3 ZHU Lu3

Cite this article:

LI Chengyin1 XU Yifang1 ZHAO Jingling2 GONG Hongwei1 JU Mengying3 YANG Jie3 ZHU Lu3. Clinical observation of the effect of Jianpi Yangxue Decoction combined with chemotherapy of gastric cancer#br#[J]. 中国医药导报, 2022, 19(8): 89-92.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I8/89

[1] Ferlay J，Colombet M，Soerjomataram I，et al. Cancer statistics for the year 2020：An overview [J]. Int J Cancer，2021，149（4）：778-789.
[2] 刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021，7（2）：1-14.
[3] 李兰.奥沙利铂联合替吉奥治疗胃癌的效果[J].临床合理用药杂志，2020，13（25）：72-73.
[4] 石正伟.参芪扶正注射液联合SOX化疗方案对晚期胃癌患者的影响[J].医学理论与实践，2020，33（17）：2843-2845.
[5] 王琦苑，李成银，朱晶，等.借助中医传承辅助平台总结罗秀丽教授治疗胃癌临床经验[J].中西医结合研究，2020， 12（1）：12-16.
[6] 龚红卫，李成银，罗秀丽.健脾益气消瘀法联合化疗治疗老年中晚期胃癌临床研究[J].四川中医，2019，37（1）：130-134.
[7] 董智平，张静喆.中医治疗胃癌研究进展[J].中国中西医结合外科杂志，2019，25（2）：206-209.
[8] 陈豪，吕书勤.胃癌的中医药治疗研究概况[J].新疆中医药，2019，37（2）：76-77.
[9] 国家食品药品监督管理局.中药新药临床研究指导原则（试行）[J].北京：中国医药科技出版社，2002：39-55， 239-243.
[10] 中华人民共和国国家卫生健康委员会.胃癌诊疗规范（2018年版）[J].肿瘤综合治疗电子杂志，2019，5（1）：55-82.
[11] 李进.肿瘤内科诊治策略[M].北京：科技出版社，2020：307-308.
[12] 王燕婷，戴媛媛，杨珺，等.细胞毒化疗药物不良反应支持治疗的指南进展及实践总结[J].中国药学杂志，2020， 55（20）：1726-1735.
[13] 史艳侠，邢镨元，张俊，等.肿瘤化疗导致的中性粒细胞减少诊治专家共识（2019年版）[J].中国医学前沿杂志：电子版，2019，11（12）：86-92.
[14] 徐瑞华，石远凯，冯继锋，等.中国肿瘤化疗相关性血小板减少症专家诊疗共识（2019版）[J].中国医学前沿杂志：电子版，2020，12（1）：51-58.
[15] 史艳侠，邢镨元，张俊，等.中国肿瘤化疗相关贫血诊治专家共识（2019年版）[J].中国医学前沿杂志：电子版，2019，11（12）：78-85.
[16] 杨之洵，郑荣寿，张思维，等.中国胃癌发病趋势及预测[J].中国肿瘤，2019，28（5）：321-326.
[17] 徐明，唐澍，刘琦.槐耳颗粒联合紫杉醇和奥沙利铂治疗晚期胃癌的临床研究[J].中国医药导报，2020，17（19）：97-100.
[18] 刘秀彬，王猛，田静，等.中医中药在胃癌化疗应用的研究进展[J].中国中西医结合外科杂志，2019，25（4）：636-640.
[19] 翟宏芳，刘爱娟，陈明达，等.复方斑蝥胶囊联合mFOLFOX6化疗方案对胃癌术后患者的临床研究[J].中国医药导报，2020，17（14）：106-109.
[20] 朱金霞，周思雨.浅析胃癌的中医药治疗[J].中医临床研究，2018，10（24）：107-108.
[21] 李佑民，李成银.健脾养血汤联合化疗治疗中晚期非小细胞肺癌40例[J].光明中医，2012，27（1）：108-109.
[22] 宋叶，林东，梅全喜，等.太子参化学成分及药理作用研究进展[J].中国药师，2019，22（8）：1506-1510.
[23] 李学臣，张涛，魏晓东.三棱提取物对H22荷瘤小鼠的抑瘤作用[J].黑龙江医药科学，2010，33（5）：78.
[24] 徐立春，陈平，孙振华，等.莪术醇瘤苗治疗胃癌的实验研究[J].现代肿瘤医学，2008，16（12）：2066-2069.
[25] 钟婵，张涛，黄李冰雪，等.健脾养胃方防治胃癌的网络药理学机制研究[J].中华中医药学刊，2020，38（5）：136-142，278-279.
[26] 龙云珺，卓德斌.益气健脾活血法联合化学药物治疗中晚期胃癌疗效与安全性的Meta分析[J].中国医药科学，2021，11（10）：22-25.
[27] 张健烽，刘云霞，徐叶峰，等.中医药联合化疗治疗胃癌术后疗效Meta分析[J].中华中医药学刊，2019，37（8）：1819-1825.
[28] 赵晔，蒋益兰，唐建清.蒋益兰从脾胃论治老年中晚期胃癌经验[J].湖南中医杂志，2020，36（7）：21-23.